Concurrent Chemoradiotherapy for Cervical Cancer: Background Including Evidence-based Data, Pitfalls of the Data, Limitation of Treatment in Certain Groups

Overview

Journal Chin J Cancer Res

Specialty Oncology

Date 2016 May 21

PMID 27199520

Citations 20

Authors

Yukiharu Todo

Hidemichi Watari

Affiliations

Soon will be listed here.

Abstract

Concurrent chemoradiotherapy (CCRT) is regarded as the standard treatment for locally advanced uterine cervical cancer (LACC), including stage Ib2-IVa disease [International Federation of Gynecology and Obstetrics (FIGO) staging]. However, approximately a third of eligible patients in previous studies died of LACC despite receiving CCRT. The therapeutic significance of CCRT alone in stage III-IVa disease has not yet been confirmed. Effective treatment of some LACC is beyond the scope of CCRT. The objective of the present review is to highlight some challenging work aimed at overcoming this seemingly intractable disease. CCRT with increased peak concentrations of cisplatin (CDDP), surgery following CCRT, adjuvant chemotherapy (CT) following CCRT, and neoadjuvant CT followed by CCRT are strategies expected to enhance the therapeutic efficacy of CCRT. If patients with LACC were divided into those with low-risk or high-risk systemic disease or prognoses, novel strategies should be assessed in the group with high-risk disease.

Citing Articles

Study of alloferon, a novel immunomodulatory antimicrobial peptide (AMP), and its analogues.

Appiah C, Chen S, Pori A, Retyunskiy V, Tzeng C, Zhao Y Front Pharmacol. 2024; 15:1359261.

PMID: 38434708 PMC: 10904621. DOI: 10.3389/fphar.2024.1359261.

The potential of PCNA inhibition as a therapeutic strategy in cervical cancer.

Wendel S, Snow J, Gu L, Banerjee N, Malkas L, Wallace N J Med Virol. 2023; 95(11):e29244.

PMID: 38010649 PMC: 10683864. DOI: 10.1002/jmv.29244.

The relationship between the radiation dose of pelvic-bone marrow and lymphocytic toxicity in concurrent chemoradiotherapy for cervical cancer.

Zhang B, Li Y, Xu L, Chai Y, Qu C, Cao Y Radiat Oncol. 2023; 18(1):12.

PMID: 36658595 PMC: 9854027. DOI: 10.1186/s13014-023-02205-8.

Nimotuzumab combined with chemoradiotherapy for the treatment of cervical cancer: A meta-analysis of randomized controlled trials.

Yuan Y, Chen J, Fang M, Guo Y, Sun X, Yu D Front Oncol. 2022; 12:994726.

PMID: 36263226 PMC: 9573994. DOI: 10.3389/fonc.2022.994726.

Efficacy and safety of endostar combined with chemoradiotherapy versus chemoradiotherapy alone in locally advanced cervical cancer: A PRISMA-compliant systematic review and meta-analysis.

Maimaitiming N, Ma X, Wei Y, Cao L, Gao Y, Zhang L Medicine (Baltimore). 2022; 101(36):e30170.

PMID: 36086700 PMC: 10980378. DOI: 10.1097/MD.0000000000030170.

References

Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X . Annual report on status of cancer in China, 2010. Chin J Cancer Res. 2014; 26(1):48-58. PMC: 3937758. DOI: 10.3978/j.issn.1000-9604.2014.01.08. View

Ryu S, Lee W, Kim K, Park S, Kim B, Kim M . Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2011; 81(4):e577-81. DOI: 10.1016/j.ijrobp.2011.05.002. View

Eifel P, Winter K, Morris M, Levenback C, Grigsby P, Cooper J . Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol. 2004; 22(5):872-80. DOI: 10.1200/JCO.2004.07.197. View

McCormack M, Kadalayil L, Hackshaw A, Hall-Craggs M, Symonds R, Warwick V . A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br J Cancer. 2013; 108(12):2464-9. PMC: 3694233. DOI: 10.1038/bjc.2013.230. View

Houvenaeghel G, Lelievre L, Gonzague-Casabianca L, Buttarelli M, Moutardier V, Goncalves A . Long-term survival after concomitant chemoradiotherapy prior to surgery in advanced cervical carcinoma. Gynecol Oncol. 2005; 100(2):338-43. DOI: 10.1016/j.ygyno.2005.08.047. View

Lim A, Sia S . Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience. Int J Radiat Oncol Biol Phys. 2011; 82(4):1431-8. DOI: 10.1016/j.ijrobp.2011.04.047. View

Nagase S, Inoue Y, Umesaki N, Aoki D, Ueda M, Sakamoto H . Evidence-based guidelines for treatment of cervical cancer in Japan: Japan Society of Gynecologic Oncology (JSGO) 2007 edition. Int J Clin Oncol. 2010; 15(2):117-24. DOI: 10.1007/s10147-010-0061-x. View

Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H . Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol. 2002; 20(4):966-72. DOI: 10.1200/JCO.2002.20.4.966. View

Bonomi P, Blessing J, Stehman F, Disaia P, Walton L, Major F . Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1985; 3(8):1079-85. DOI: 10.1200/JCO.1985.3.8.1079. View

10.

Kim T, Park B, Kwack H, Kwon J, Kim J, Yoon S . Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation. J Obstet Gynaecol Res. 2012; 38(11):1315-20. DOI: 10.1111/j.1447-0756.2012.01871.x. View

11.

Perez C, Grigsby P, Lockett M . Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiat Oncol Biol Phys. 1995; 32(5):1275-88. DOI: 10.1016/0360-3016(95)00220-S. View

12.

Mikami M, Aoki Y, Sakamoto M, Shimada M, Takeshima N, Fujiwara H . Surgical principles for managing stage IB2, IIA2, and IIB uterine cervical cancer (Bulky Tumors) in Japan: a survey of the Japanese Gynecologic Oncology Group. Int J Gynecol Cancer. 2014; 24(7):1333-40. DOI: 10.1097/IGC.0000000000000202. View

13.

Legge F, Margariti P, Lucidi A, Macchia G, Petrillo M, Iannone V . Completion surgery after concomitant chemoradiation in obese women with locally advanced cervical cancer: Evaluation of toxicity and outcome measures. Acta Oncol. 2012; 52(1):166-73. DOI: 10.3109/0284186X.2012.698753. View

14.

Whitney C, Sause W, Bundy B, MALFETANO J, Hannigan E, Fowler Jr W . Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999; 17(5):1339-48. DOI: 10.1200/JCO.1999.17.5.1339. View

15.

Delpech Y, Haie-Meder C, Rey A, Zafrani Y, Uzan C, Gouy S . Para-aortic involvement and interest of para-aortic lymphadenectomy after chemoradiation therapy in patients with stage IB2 and II cervical carcinoma radiologically confined to the pelvic cavity. Ann Surg Oncol. 2007; 14(11):3223-31. DOI: 10.1245/s10434-007-9526-1. View

16.

Mariagrazia D, Anna F, Gabriella F, Francesco F, Daniela S, Giuseppe D . Preoperative chemoradiotherapy in locally advanced cervical cancer: long-term outcome and complications. Gynecol Oncol. 2005; 99(3 Suppl 1):S166-70. DOI: 10.1016/j.ygyno.2005.07.074. View

17.

Classe J, Rauch P, Rodier J, Morice P, Stoeckle E, Lasry S . Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer: morbidity and outcome: results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer). Gynecol Oncol. 2006; 102(3):523-9. DOI: 10.1016/j.ygyno.2006.01.022. View

18.

Thigpen T, SHINGLETON H, Homesley H, Lagasse L, Blessing J . cis-Dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group. Cancer Treat Rep. 1979; 63(9-10):1549-55. View

19.

Kudaka W, Nagai Y, Toita T, Inamine M, Asato K, Nakamoto T . Long-term results and prognostic factors in patients with stage III-IVA squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy from a single institution study. Int J Clin Oncol. 2012; 18(5):916-21. DOI: 10.1007/s10147-012-0457-x. View

20.

Morris M, Eifel P, Lu J, Grigsby P, Levenback C, STEVENS R . Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999; 340(15):1137-43. DOI: 10.1056/NEJM199904153401501. View